- Home
- KREF vs ETNB Comparison
KREF vs ETNB Comparison
Compare KREF & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KREF
- ETNB
- Stock Information
- Founded
- KREF 2014
- ETNB 2018
- Country
- KREF United States
- ETNB United States
- Employees
- KREF N/A
- ETNB N/A
- Industry
- KREF Real Estate Investment Trusts
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- KREF Real Estate
- ETNB Health Care
- Exchange
- KREF Nasdaq
- ETNB Nasdaq
- Market Cap
- KREF 784.1M
- ETNB 867.4M
- IPO Year
- KREF 2017
- ETNB 2019
- Fundamental
- Price
- KREF $10.61
- ETNB $7.52
- Analyst Decision
- KREF Buy
- ETNB Buy
- Analyst Count
- KREF 6
- ETNB 7
- Target Price
- KREF $12.75
- ETNB $30.33
- AVG Volume (30 Days)
- KREF 350.3K
- ETNB 794.5K
- Earning Date
- KREF 02-04-2025
- ETNB 11-07-2024
- Dividend Yield
- KREF 9.22%
- ETNB N/A
- EPS Growth
- KREF N/A
- ETNB N/A
- EPS
- KREF N/A
- ETNB N/A
- Revenue
- KREF $66,587,000.00
- ETNB N/A
- Revenue This Year
- KREF N/A
- ETNB N/A
- Revenue Next Year
- KREF N/A
- ETNB N/A
- P/E Ratio
- KREF N/A
- ETNB N/A
- Revenue Growth
- KREF 9.58
- ETNB N/A
- 52 Week Low
- KREF $8.71
- ETNB $7.00
- 52 Week High
- KREF $14.12
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- KREF 33.42
- ETNB 44.02
- Support Level
- KREF $10.78
- ETNB $7.44
- Resistance Level
- KREF $11.70
- ETNB $8.09
- Average True Range (ATR)
- KREF 0.25
- ETNB 0.44
- MACD
- KREF -0.05
- ETNB -0.06
- Stochastic Oscillator
- KREF 13.53
- ETNB 22.47
About KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).